Pfizer: Lyrica fails to meet primary endpoint in phase III

(CercleFinance.com) - Pfizer's Lyrica has failed to meet its primary endpoint in a Phase 3 study to assess the drug's use as an adjunctive therapy for patients suffering from epilepsy, the company said on Monday.


Treatment with Lyrica has not resulted in a statistically significant reduction versus placebo in epilepsy patients of 5 to 65 years of age with primary generalized tonic-clonic seizures, it said.

Lyrica is indicated to treat fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults.

In the US, the drug has been approved as adjunctive therapy for the treatment of partial onset seizures in patients of at least four years of age.

Copyright (c) 2019 CercleFinance.com. All rights reserved.